XIFAXAN 550 mg Tablets Offer First Clinical Treatment Option in the United States for Patients with Overt HE in More Than 30 Years RALEIGH, NC, March 24, 2010 - Salix Pharmaceuticals, Ltd.
RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on March 7, 2011 for ...
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug ...
LAVAL, Quebec, May 27, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received ...
The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation. The FDA's tentative approval of rifaximin 550 mg ...
US FDA Committee recommends approval of Salix's rifaximin tablets, 550 mg for hepatic encephalopathy
Salix Pharmaceuticals, Ltd. reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favour of the approval of Xifaxan (rifaximin) tablets, 550 mg ...
Shares of Bausch Health Companies, Inc. BHC gained 5.3% after it obtained a favorable ruling from the U.S. District Court of Delaware for one of its top drugs, Xifaxan (rifaximin). Xifaxan 550 mg ...
Bausch Health, its Salix business unit, and Salix’s licensor Alfasigma, have agreed to resolve outstanding intellectual property disputes with Sun Pharmaceuticals regarding Xifaxan (rifaximin) 200-mg ...
BRIDGEWATER, N.J., Oct. 1, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results